African Journal of Biotechnology
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
African Journal of Biotechnology Vol. 4 (11), pp. 1317-1320, November 2005
Comparative
assessment of Plasmodium falciparum sensitivity to chloroquine and
amodiaquine in vitro
OYEDEJI, Segun Isaac1, BASSI, Peter Usman2*,
AWOBODE, Henrietta Oluwatoyin3 and OLUMESE Peter Ehibizue1
1University College
Hospital Ibadan, Oyo State, Nigeria.
2University of
Maiduguri teaching hospital Maiduguri, Borno state Nigeria.
3Department of Zoology
University of Ibadan Nigeria.
*Corresponding author. E-mail:
pubassi@yahoo.com.
Tel: 08034945067, 234-076-370782, Fax:
234-076-234666.
Accepted 2 September, 2005 |
||||
| Abstract | |||||
|
|
The in vitro sensitivity of Plasmodium falciparum isolates to chloroquine and amodiaquine were assessed in children with symptomatic uncomplicated malaria in Ibadan, Nigeria. The WHO standard in vitro micro-test method was employed for the study. A total of one hundred and two children were admitted into the study. Inhibition of schizont maturation at varying concentration of the study drugs was used as an index for drug activity. Effective concentrations by probit analysis of log dose/response for 50, 90 and 99% (EC50, EC90and EC99) inhibition were 0.37, 2.38 and 5.76 μmol/l, respectively, for chloroquine and 0.06, 0.26 and 0.59 μmol/l, respectively, for amodiaquine. Forty isolates of P. falciparum were tested for chloroquine sensitivity. Eighty percent (32/40) showed schizont maturation at 1.6 μmol/l and were classified as resistant, while 39% (14/36) of isolates tested for amodiaquine matured at 0.4 μmol/l and were also classified as resistant. This shows that amodiaquine is significantly more effective than chloroquine. While this data provides no absolute demonstration of chloroquine resistance, it underlies the need for continuous monitoring of the susceptibility of P. falciparum to chloroquine in southwest Nigeria.
Key words: Plasmodium falciparum, chloroquine, amodiaquine, in vitro, resistance.
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |